abstract |
Provided are injectable compositions comprising a therapeutic peptide, an alkyl N,N-disubstituted amino acetate and a physiologically acceptable carrier. The preferred therapeutic peptides include insulin, rituximab and liraglutide. The preferred alkyl N,N-disubstituted amino acetate is dodecyl 2-(N,N-dimethylamino) propionate (DDAIP). |